Compare Quest Diagnostics Inc (DGX) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs S&P500 ETF — how do they compare? Quest Diagnostics Inc trades at $230.44 (market cap $25.48B), while S&P500 ETF trades at $777.36 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 32.2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and S&P500 ETF for 205 Days on average.
| DGX | SPY | |
|---|---|---|
Market Cap | $25.48B | $821.54B |
Volume | 941,866 | 40,070,358 |
Sector | Health | — |
52-Week High | $247.45 | $779.14 |
52-Week Low | $173.49 | $631.99 |
Typical Hold Time | 56 Days | 205 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
SPY, tracking the S&P 500, trades at $775.78, down 0.19% on the day amid a mixed technical backdrop with a bullish moving average signal but neutral oscillators. The ETF shows no available fundamental ratios in this snapshot, and a dividend of $1.89 is scheduled for payment in October 2026. Recent news highlights market volatility, with articles discussing valuation concerns and sector rotations.
The outlook for SPY hinges on broader market trends, with technical support near $771 offering a cushion. Risks include potential earnings growth slowdowns and macroeconomic pressures, but the bullish moving average alignment suggests underlying strength for long-term investors focused on U.S. equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
